Axa
NKTR icon

Axa’s Nektar Therapeutics NKTR Stock Holding History

Axa’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,833
Closed -$876K – 1154
2022
Q4 		$876K Sell
25,833
-1,140
-4% -$55.2K ﹤0.01% 908
2022
Q3 		$1.29M Hold
26,973
– – 0.01% 822
2022
Q2 		$1.54M Buy
26,973
+23,526
+683% +$1.48M 0.01% 811
2022
Q1 		$279K Buy
+3,447
New +$510K ﹤0.01% 1115
2018
Q4 		– Sell
-18,157
Closed -$16.6M – 1350
2018
Q3 		$16.6M Buy
+18,157
New +$15.5M 0.06% 345
2018
Q2 		– Sell
-947
Closed -$1.51M – 1388
2018
Q1 		$1.51M Buy
+947
New +$1.22M 0.01% 916
2015
Q1 		– Sell
-11,504
Closed -$2.67M – 1469
2014
Q4 		$2.67M Sell
11,504
-11,750
-51% -$2.51M 0.01% 717
2014
Q3 		$4.21M Sell
23,254
-150
-0.6% -$28.7K 0.02% 578
2014
Q2 		$4.5M Sell
23,404
-941
-4% -$166K 0.02% 574
2014
Q1 		$4.43M Buy
24,345
+1,268
+5% +$251K 0.02% 555
2013
Q4 		$3.93M Buy
23,077
+1,148
+5% +$185K 0.02% 587
2013
Q3 		$3.44M Buy
21,929
+4,811
+28% +$889K 0.02% 618
2013
Q2 		$2.97M Buy
+17,118
New +$2.63M 0.02% 613

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa's NKTR Position: Q1 2023 in Review

Axa sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 25,833 shares — an estimated $876K sold.

Axa first reported a position in NKTR in Q2 2013 and held it in 13 quarters. The position peaked at $16.6M in Q3 2018. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • Axa reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Axa sold 25,833 Nektar Therapeutics shares in Q1 2023, an estimated $876K.
  • Axa first reported a position in Nektar Therapeutics in Q2 2013 and held it in 13 quarters.
  • Axa's Nektar Therapeutics position peaked at $16.6M in Q3 2018.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.